AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Amgen stock popped Tuesday after the biotech company's AstraZeneca-partnered asthma treatment succeeded in a Phase 3 test. The post Amgen, AstraZeneca Stocks Pop On 'Best-Case' Outcome For Asthma Drug appeared first on Investor's Business Daily.

Amgen, AstraZeneca Stocks Pop On 'Best-Case' Outcome For Asthma Drug

Pfizer

BioNTech SE

Johnson & Johnson

Moderna

Novavax

A safe and effective Covid-19 vaccine is seen by investors and policymakers as a solution to get the global economy back on track.

Coronavirus vaccine frontrunner Pfizer delivers key trial data – here's where the other vaccines stand

There's no question that the big drugmaker has plenty to offer investors. But is that enough?

3 Reasons to Buy AstraZeneca Stock and 1 Reason to Sell

AstraZeneca's (AZN) CEO Pascal Soriot on Q3 2020 Results - Earnings Call Transcript

The pharmaceutical company is also starting a phase 3 trial of its combination antibody treatment.

AstraZeneca Expects Coronavirus Vaccine Trial Results by End of Year

AstraZeneca announced Wednesday that it still expects results from phase three of its COVID-19 vaccine trial to be ready by the end of 2020.

AstraZeneca expects COVID-19 phase 3 trial results 'later this year' after pause

AstraZeneca (AZN) lags Q3 earnings estimates and surpasses the same for sales. It maintains its financial outlook for the year.

AstraZeneca (AZN) Q3 Earnings Miss Estimates, Sales Beat

The prediction was the latest suggestion from a major drugmaker that the race to produce a vaccine for the deadly COVID-19 bug could reach a significant milestone in the coming months.

AstraZeneca expects COVID-19 vaccine results by year's end

Bloomberg reported Thursday that AstraZeneca Plc (NASDAQ: AZN) missed earnings expectations in the third quarter of 2020. The Cambridge headquartered biopharma company reported $6.6 billion in revenues and a core diluted EPS of $0.94.

AstraZeneca Misses Q3 Earnings Consensus, Expects Covid-19 Vaccine Trial Results This Year

AstraZeneca will start discussing emergency approval of its experimental COVID-19 vaccine with U.S. regulators once it has good trial data from Britain, South Africa and Brazil, as it has no indication the watchdog would favour U.S. data.

AstraZeneca aims to bring non-U.S. vaccine data before the FDA

In a report on Thursday, AstraZeneca plc (LON: AZN) said that its net profit posted an over 100% annualised growth in the fiscal third quarter. Core earnings and revenue, however, were slightly lower than what analysts had anticipated.

AstraZeneca says net profit jumped more than 100% in the third quarter

British pharmaceutical giant AstraZeneca said Thursday it expects vaccine data to be available this year as it reported a solid rise in third-quarter sales.

Covid vaccine maker AstraZeneca expects to release trial data by year-end

AstraZeneca , the British drugmaker working on one of the world's leading COVID-19 vaccine candidates, on Thursday beat third-quarter sales estimates on strong demand for its diverse portfolio of drugs during COVID-19 pandemic lockdowns and maintained its 2020 forecasts.

AstraZeneca beats third-quarter sales estimate, backs 2020 outlook

AstraZeneca plc (NYSE: AZN) has received the regulatory nod to conduct clinical trials of its COVID-19 vaccine in Chile and Peru, Reuters reported Wednesday. What Happened: Chile's President Sebastian Pinera said that his nation's health regulator had approved the British company's vaccine trial, according to Reuters.

AstraZeneca Gets Chile, Peru Nod To Resume COVID-19 Vaccine Trials

Australia has agreed to purchase another 50 million doses of two more COVID-19 vaccines, Prime Minister Scott Morrison said on Thursday, as Canberra aims to complete a mass inoculation programme within months.

Australia signs two more COVID-19 vaccine deals

Bristol-Myers

Eli Lilly

Divided government could be good news for big pharma.

Why AstraZeneca, Bristol Myers Squibb, and Eli Lilly Stocks Jumped Today

The University of Oxford hopes to present late-stage trial results on its COVID-19 vaccine candidate, being developed with AstraZeneca, later this year

Oxford vaccine-trial chief sees ‘small chance' of COVID-19 inoculations being ready by Christmas

Andrew Pollard, director of the Oxford University COVID-19 vaccine trial, said Wednesday there was a "small chance" the jab will be ready before December 25. The vaccine, developed by Oxford University and AstraZeneca, is one of the world's leading vaccine candidates. 

There's a 'small chance' Oxford University's COVID-19 vaccine will be ready this year, according to the director of its clinical trial

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback the hedge funds employing these talents and can benefit from their vast resources and knowledge in that way. We analyze quarterly 13F filings of nearly 823 hedge funds and, by looking at the smart money sentiment that surrounds a stock, we can determine whether it has the potential to beat the market over the long-term. Therefore, let's take a closer look at what smart money thinks about AstraZeneca plc (NYSE:AZN).

These Hedge Funds Were Wrong About AstraZeneca plc (AZN)

Fusion Pharmaceuticals

Collaboration Combines Fusion's Targeted Alpha Therapies (TATs) Platform with AstraZeneca's Antibody and Oncology Portfolio to Create Novel Cancer Therapies Fusion to Host a Conference Call at 8:30am ET HAMILTON, ON and BOSTON, Nov. 2, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc....

Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies

No, the familiar "this will only sting a little" you hear from healthcare providers isn't one of them.

3 Things About Coronavirus Vaccines That You Almost Certainly Won't Like

There are still many hurdles in the way of AstraZeneca's coronavirus vaccine candidate.

Should You Be Worried About AstraZeneca Stock?

The U.K. drug regulator is accelerating reviews of the coronavirus vaccines being developed by Pfizer and AstraZeneca, according to a report.

Regulators are accelerating reviews of COVID-19 vaccines from Pfizer and AstraZeneca, according to a report

Gilead Sciences

Update on the COVID Vaccine Race

PFE/BNTX and MRNA remain the front-runners in the race to develop a COVID-19 vaccine. PFE has seen some delays but at least, we haven't passed an interim analysis without success.

News for AstraZeneca Stock (AZN)